NO991776L - Aminotiofenkarboksylsyreamider og anvendelse derav som fosfodiesteraseinhibitorer - Google Patents
Aminotiofenkarboksylsyreamider og anvendelse derav som fosfodiesteraseinhibitorerInfo
- Publication number
- NO991776L NO991776L NO991776A NO991776A NO991776L NO 991776 L NO991776 L NO 991776L NO 991776 A NO991776 A NO 991776A NO 991776 A NO991776 A NO 991776A NO 991776 L NO991776 L NO 991776L
- Authority
- NO
- Norway
- Prior art keywords
- acid amides
- phosphodiesterase inhibitors
- aminothiophenecarboxylic
- aminothiophenecarboxylic acid
- phosphodiesterase
- Prior art date
Links
- BKDZTJNNXCNSCK-UHFFFAOYSA-N 3-aminothiophene-2-carboxamide Chemical class NC(=O)C=1SC=CC=1N BKDZTJNNXCNSCK-UHFFFAOYSA-N 0.000 title 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 title 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19642451A DE19642451A1 (de) | 1996-10-15 | 1996-10-15 | Aminothiophencarbonsäureamide |
| PCT/EP1997/005531 WO1998016521A1 (de) | 1996-10-15 | 1997-10-08 | Aminothiophencarbonsäureamide und ihre verwendung als phosphodiesterase inhibitoren |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO991776D0 NO991776D0 (no) | 1999-04-14 |
| NO991776L true NO991776L (no) | 1999-06-09 |
Family
ID=7808775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO991776A NO991776L (no) | 1996-10-15 | 1999-04-14 | Aminotiofenkarboksylsyreamider og anvendelse derav som fosfodiesteraseinhibitorer |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6143777A (cs) |
| EP (1) | EP0934301B1 (cs) |
| JP (1) | JP4243352B2 (cs) |
| KR (1) | KR100479811B1 (cs) |
| CN (1) | CN1110493C (cs) |
| AR (1) | AR009985A1 (cs) |
| AT (1) | ATE202347T1 (cs) |
| AU (1) | AU725741B2 (cs) |
| BR (1) | BR9712321A (cs) |
| CA (1) | CA2268886C (cs) |
| CZ (1) | CZ297253B6 (cs) |
| DE (2) | DE19642451A1 (cs) |
| DK (1) | DK0934301T3 (cs) |
| ES (1) | ES2159851T3 (cs) |
| GR (1) | GR3036341T3 (cs) |
| HU (1) | HUP9904703A3 (cs) |
| NO (1) | NO991776L (cs) |
| PL (1) | PL192109B1 (cs) |
| PT (1) | PT934301E (cs) |
| RU (1) | RU2184731C2 (cs) |
| SI (1) | SI0934301T1 (cs) |
| SK (1) | SK283807B6 (cs) |
| TW (1) | TW438791B (cs) |
| WO (1) | WO1998016521A1 (cs) |
| ZA (1) | ZA979199B (cs) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6727258B2 (en) * | 1997-10-29 | 2004-04-27 | King Pharmaceutical Research & Development, Inc. | Allosteric adenosine receptor modulators |
| US6410584B1 (en) | 1998-01-14 | 2002-06-25 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells with indole derivatives |
| WO1999067202A1 (en) * | 1998-06-19 | 1999-12-29 | Syngenta Participations Ag . | Process for preparation of pyrimidinone derivatives |
| US6200771B1 (en) | 1998-10-15 | 2001-03-13 | Cell Pathways, Inc. | Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia |
| US6133271A (en) * | 1998-11-19 | 2000-10-17 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives |
| US6187779B1 (en) | 1998-11-20 | 2001-02-13 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives |
| US6369092B1 (en) | 1998-11-23 | 2002-04-09 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted benzimidazole derivatives |
| US6077842A (en) * | 1998-11-24 | 2000-06-20 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives |
| US6034099A (en) * | 1998-11-24 | 2000-03-07 | Cell Pathways, Inc. | Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones |
| US6486155B1 (en) | 1998-11-24 | 2002-11-26 | Cell Pathways Inc | Method of inhibiting neoplastic cells with isoquinoline derivatives |
| US6020379A (en) * | 1999-02-19 | 2000-02-01 | Cell Pathways, Inc. | Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia |
| US6479493B1 (en) | 2001-08-23 | 2002-11-12 | Cell Pathways, Inc. | Methods for treatment of type I diabetes |
| ES2307780T3 (es) * | 2001-09-21 | 2008-12-01 | Smithkline Beecham Corporation | Compuestos quimicos. |
| ES2315430T3 (es) * | 2001-10-04 | 2009-04-01 | Smithkline Beecham Corporation | Inhibidores de nf-kb. |
| US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| US7276529B2 (en) | 2002-03-20 | 2007-10-02 | Celgene Corporation | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
| US7208516B2 (en) | 2002-03-20 | 2007-04-24 | Celgene Corporation | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
| AU2003255148A1 (en) * | 2002-07-24 | 2004-02-09 | Mitsui Chemicals, Inc. | Process for producing 2-alkyl-3-aminothiophene derivative |
| US7179836B2 (en) * | 2002-09-20 | 2007-02-20 | Smithkline Beecham Corporation | Chemical compounds |
| BRPI0418351A (pt) * | 2004-01-05 | 2007-05-08 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, métodos de limitar a proliferação celular em um humano ou animal, de tratamento de um humano ou animal sofrendo de cáncer, de tratamento de profilaxia de cáncer, de tratamento de um humano ou animal sofrendo de uma doença neoplásica, de tratamento de um humano ou animal sofrendo de uma doença prolifetativa de tratamento de cáncer, para o tratamento de infecções associadas com cáncer, para o tratamento profilático de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método de inibir a chk1 quinase, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo |
| FR2875807B1 (fr) | 2004-09-30 | 2006-11-17 | Servier Lab | Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
| BRPI0609515A8 (pt) * | 2005-03-23 | 2017-12-26 | Actelion Pharmaceuticals Ltd | Composto, composição farmacêutica, e, uso de um composto |
| US7678363B2 (en) | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| CA2625153A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| JP2009513672A (ja) | 2005-10-31 | 2009-04-02 | ブレインセルス，インコーポレイティド | 神経発生のｇａｂａ受容体媒介調節 |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| JP2009536667A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス，インコーポレイティド | ５ｈｔ受容体介在性の神経新生 |
| JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス，インコーポレイティド | アンジオテンシン調節による神経新生 |
| AU2007292848A1 (en) * | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| CA2734500A1 (en) * | 2008-08-27 | 2010-03-11 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| RU2503671C1 (ru) * | 2012-07-31 | 2014-01-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" | (Z)-2-[(3-КАРБАМОИЛ-4,5,6,7-ТЕТРАГИДРОБЕНЗО[b]ТИЕН-2-ИЛ)АМИНО]-4-(4-R-ФЕНИЛ)-4-ОКСОБУТ-2-ЕНОВЫЕ КИСЛОТЫ, ОБЛАДАЮЩИЕ АНАЛЬГЕТИЧЕСКОЙ АКТИВНОСТЬЮ |
| RU2501795C1 (ru) * | 2012-10-01 | 2013-12-20 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" | N-R-АМИДЫ (Z)-2[(3-ЭТОКСИКАРБОНИЛ)-4,5,6,7-ТЕТРАГИДРОБЕНЗО[b]ТИЕН-2-ИЛ)АМИНО]-4-ФЕНИЛ-4-ОКСОБУТ-2-ЕНОВЫХ КИСЛОТ, ОБЛАДАЮЩИЕ АНАЛЬГЕТИЧЕСКОЙ АКТИВНОСТЬЮ |
| EP3157520B1 (en) | 2014-06-23 | 2019-09-04 | Celgene Corporation | Apremilast for the treatment of a liver disease or a liver function abnormality |
| PT3796975T (pt) | 2018-05-22 | 2023-11-15 | Orsobio Inc | Derivados de sulfonilaminobenzamida |
| RU2722176C1 (ru) * | 2019-09-06 | 2020-05-28 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" | (z)-2((4-r1-5-r2-3-(этоксикарбонил)тиофен-2-ил)амино)-4-оксо-4-r3-бут-2-еновые кислоты, обладающие противомикробной активностью |
| US20230278978A1 (en) * | 2020-07-24 | 2023-09-07 | Inipharm, Inc. | Thiophene hsd17b13 inhibitors and uses thereof |
| EP4244210A4 (en) | 2020-11-13 | 2024-10-30 | Inipharm, Inc. | Dichlorophenol hsd17b13 inhibitors and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5075310A (en) * | 1988-07-01 | 1991-12-24 | Smith Kline & French Laboratories, Ltd. | Pyrimidone derivatives as bronchodilators |
| US5047555A (en) * | 1988-12-13 | 1991-09-10 | Tanabe Seiyaku Co., Ltd. | 4-aminophenol derivatives and processes for preparing the same |
| US5753692A (en) * | 1992-02-19 | 1998-05-19 | Industrial Technology Research Institute | Medicinal thiophene compounds |
| US5356926A (en) * | 1992-02-24 | 1994-10-18 | Warner-Lambert Company | 3-alkyloxy-, aryloxy-, or arylalkyloxy-benzo [β]thiophene-2-carboxamides as inhibitors of cell adhesion |
| DE4230755A1 (de) * | 1992-09-14 | 1994-03-17 | Schering Ag | Verwendung von PDE-Inhibitoren bei der Behandlung von Nieren- und Ureter-Erkrankungen |
| DE4233198A1 (de) * | 1992-10-02 | 1994-04-07 | Bayer Ag | Substituierte Thiophencarbonsäureamide |
| DK148292D0 (da) * | 1992-12-09 | 1992-12-09 | Lundbeck & Co As H | Forbindelser |
| GB9309324D0 (en) * | 1993-05-06 | 1993-06-16 | Bayer Ag | Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives |
| DE4317076A1 (de) * | 1993-05-21 | 1994-11-24 | Bayer Ag | Benzthiophencarbonsäureamid-S-oxide |
| DK0685475T3 (da) * | 1994-05-31 | 1999-08-30 | Bayer Ag | Amino-benzofuryl- og thienylderivater |
| US5863936A (en) * | 1995-04-18 | 1999-01-26 | Geron Corporation | Telomerase inhibitors |
| AU4652697A (en) * | 1996-10-08 | 1998-05-05 | Eli Lilly And Company | New serotonin 5-ht1f agonists |
| US5783597A (en) * | 1997-03-04 | 1998-07-21 | Ortho Pharmaceutical Corporation | 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use |
-
1996
- 1996-10-15 DE DE19642451A patent/DE19642451A1/de not_active Withdrawn
-
1997
- 1997-10-06 TW TW086114589A patent/TW438791B/zh active
- 1997-10-08 PL PL332802A patent/PL192109B1/pl unknown
- 1997-10-08 JP JP51798698A patent/JP4243352B2/ja not_active Expired - Fee Related
- 1997-10-08 US US09/284,501 patent/US6143777A/en not_active Expired - Fee Related
- 1997-10-08 DK DK97912140T patent/DK0934301T3/da active
- 1997-10-08 DE DE59703869T patent/DE59703869D1/de not_active Expired - Lifetime
- 1997-10-08 SI SI9730192T patent/SI0934301T1/xx unknown
- 1997-10-08 CA CA002268886A patent/CA2268886C/en not_active Expired - Fee Related
- 1997-10-08 KR KR10-1999-7003246A patent/KR100479811B1/ko not_active Expired - Fee Related
- 1997-10-08 HU HU9904703A patent/HUP9904703A3/hu unknown
- 1997-10-08 SK SK432-99A patent/SK283807B6/sk unknown
- 1997-10-08 ES ES97912140T patent/ES2159851T3/es not_active Expired - Lifetime
- 1997-10-08 CN CN97198839A patent/CN1110493C/zh not_active Expired - Fee Related
- 1997-10-08 WO PCT/EP1997/005531 patent/WO1998016521A1/de active IP Right Grant
- 1997-10-08 PT PT97912140T patent/PT934301E/pt unknown
- 1997-10-08 CZ CZ0124099A patent/CZ297253B6/cs not_active IP Right Cessation
- 1997-10-08 EP EP97912140A patent/EP0934301B1/de not_active Expired - Lifetime
- 1997-10-08 RU RU99109576/04A patent/RU2184731C2/ru not_active IP Right Cessation
- 1997-10-08 AU AU49451/97A patent/AU725741B2/en not_active Ceased
- 1997-10-08 BR BR9712321-8A patent/BR9712321A/pt not_active Application Discontinuation
- 1997-10-08 AT AT97912140T patent/ATE202347T1/de not_active IP Right Cessation
- 1997-10-14 ZA ZA9709199A patent/ZA979199B/xx unknown
- 1997-10-15 AR ARP970104736A patent/AR009985A1/es not_active Application Discontinuation
-
1999
- 1999-04-14 NO NO991776A patent/NO991776L/no not_active Application Discontinuation
-
2001
- 2001-08-07 GR GR20010401193T patent/GR3036341T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0934301T3 (da) | Aminothiophencarboxylsyreamider og anvendelse deraf som phosphodiesteraseinhibitorer | |
| DK0922697T3 (da) | Substituerede pyrazolylbenzensulfonamider og anvendelse deraf som cyclooxygenase II-inhibitorer | |
| CY2010015I1 (el) | Φθοροαλκοξυ-υποκατεστημενα βεναμιδια και η χρησιμοποιηση τους σαν κυκλικοι-νουκλεοτιδικοι αναστολεις φωσφοδιεστερασης | |
| NO991922D0 (no) | Heteroarylsuccinamider og deres anvendelse som metalloproteinaseinhibitorer | |
| NO20012688L (no) | Benzamidderivater og anvendelse derav som APOB-100 sekresjonsinhibitorer | |
| NO20001323D0 (no) | Dipeptid-apoptose inhibitorer og deres anvendelse | |
| NO990296D0 (no) | HPPD-genet og inhibitorer | |
| FI956119L (fi) | Fenyyliheterosyklejä syklo-oksigenaasi-2-inhibiittoreina | |
| EE200100373A (et) | Bensoheterotsüklid ja nende kasutamine MEK inhibiitoritena | |
| DK0832061T3 (da) | Benzamidderivater og anvendelse deraf som vasopressin-antagonister | |
| IS4481A (is) | Díhýdrópyramídín og notkun þeirra | |
| FI965019A7 (fi) | Entsyymi-inhibiittoreita | |
| IS4906A (is) | Nýjar amínósýruafleiður og notkun þeirra sem þrombínhemla | |
| DK0944590T3 (da) | Aminoguanidiner og alkoxyguanidiner som proteaseinhibitorer | |
| NO942247D0 (no) | Korrosjonsinhibitor og anvendelse derav | |
| NO954944L (no) | Antikorrosjonspigment og anvendelse derav | |
| HUP9904165A3 (en) | 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase and use thereof | |
| IS4312A (is) | Skvalen lígasa efnahemlar og notkun theirra | |
| NO20003142D0 (no) | Substituerte isokinolin-derivater og anvendelse derav som antikrampemidler | |
| NO954321L (no) | 4-aryl-4-hydroksy-tetrahydropyraner og 3-aryl-3-hydroksy-tetrahydrofuraner som 5-lipoksygenase-inhibitorer | |
| DK1140952T3 (da) | Phosphororganiske forbindelser og anvendelse heraf | |
| DK1228026T3 (da) | 15-Hydroxyicosatetraensyrerelaterede forbindelser og fremgangsmåde til anvendelse | |
| DK1036319T3 (da) | Fremgangsmåde til opnåelse af L-dihydroorotsyre og anvendelse deraf | |
| NO983556L (no) | Formulering og anvendelse | |
| IT1292010B1 (it) | Ganasce per cristallo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |